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Estimation of the prevalence 
and incidence of motor neuron 
diseases in two Spanish regions: 
Catalonia and Valencia
Maria A. Barceló1,2,3*, Mònica Povedano3, Juan F. Vázquez‑Costa4,5,6, Álvaro Franquet1,2,7, 
Marta Solans1,2 & Marc Saez1,2 
According to the degree of upper and lower motor neuron degeneration, motor neuron diseases 
(MND) can be categorized into amyotrophic lateral sclerosis (ALS), primary lateral sclerosis (PLS) or 
progressive muscular atrophy (PMA). Although several studies have addressed the prevalence and 
incidence of ALS, there is a high heterogeneity in their results. Besides this, neither concept has been 
previously studied in PLS or PMA. Thus, the objective of this study was to estimate the prevalence 
and incidence of MND, (distinguishing ALS, PLS and PMA), in the Spanish regions of Catalonia and 
Valencia in the period 2011–2019. Two population‑based Spanish cohorts were used, one from 
Catalonia and the other from Valencia. Given that the samples that comprised both cohorts were not 
random, i.e., leading to a selection bias, we used a two‑part model in which both the individual and 
contextual observed and unobserved confounding variables are controlled for, along with the spatial 
and temporal dependence. The prevalence of MND was estimated to be between 3.990 and 6.334 per 
100,000 inhabitants (ALS between 3.248 and 5.120; PMA between 0.065 and 0.634; and PLS between 
0.046 and 1.896), and the incidence between 1.682 and 2.165 per 100,000 person‑years for MND (ALS 
between 1.351 and 1.754; PMA between 0.225 and 0.628; and PLS between 0.409–0.544). Results 
were similar in the two regions and did not differ from those previously reported for ALS, suggesting 
that the proposed method is robust and that neither region presents differential risk or protective 
factors.
Motor neuron diseases (MND) are a group of mainly sporadic neurodegenerative diseases characterised by 
a progressive loss of upper and/or lower motor neurons (UMN and LMN, respectively) that frequently leads 
to progressive paralysis and death, typically due to respiratory  failure1. Based on the degree of clinical and 
neurophysiological impairment of the UMN and LMN, MNDs are further divided into three major diagnostic 
categories: amyotrophic lateral sclerosis (ALS)—by far the most frequent MND comprising about 90% of MND 
patients—and the related diseases, primary lateral sclerosis (PLS) and progressive muscular atrophy (PMA). 
Despite sharing causes, pathology and pathophysiological mechanisms, their different prognoses and differential 
diagnoses justify their distinction in both clinical practice and  research1.
In clinical practice, different phenotypes of ALS can be distinguished based on the site of onset (i.e. bulbar, 
spinal, respiratory), the presence and degree of cognitive impairment (i.e. ALS with frontotemporal dementia or 
ALS-FTD), or the presence of causal mutations (i.e. familial vs sporadic ALS), among  others1.
PLS is characterised by a pure UMN involvement for at least four years, with a slow progression, typically 
with long-term stationary phases and frequently normal  lifespan2. The period of four years for a definitive PLS 
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diagnosis is required because LMN signs can develop in this time, and the patient is subsequently reclassified 
into the ALS  category3,4.
PMA is characterised by a pure clinical impairment of the  LMN5. Unlike PLS, there is no established definition 
for PMA, yet the distinction is considered useful for its prognostic implications, and a similar 4-year period has 
been proposed to distinguish it from the ALS forms with predominantly LMN  impairment1.
Prevalence and incidence of ALS. Recent population-based studies have reported a prevalence of ALS of 
between 4.1 and 8.4 per 100,000 inhabitants, with a pooled prevalence of about 4.4 per 100,000  inhabitants6–11.
Prevalence estimates show a marked geographical heterogeneity. In the USA, prevalences of 5 per 100,000 
have been reported for ALS  patients12–14. Furthermore, from the work carried out within the ’Global Burden of 
Disease’, also in the USA, an age-standardized prevalence of motor neuron disease was estimated as being equal 
to 9.1 per 100,000 in  200715. Meanwhile, Zapata et al. estimated a point prevalence of 4.9 per 100,000 inhabitants) 
for Antioquia, Colombia in  201416 and by combining 13 studies, Chiò et al. estimated a median crude prevalence 
of 5.4 per 100,000 for Europe, ranging from 1.1 in Yugoslavia, to 8 in the Netherlands and two Italian  regions9, 
and 8.2 in the Faroe  Islands9,17. In Asia, the prevalence is usually lower than in Western European  countries11. 
The median crude prevalence has been estimated at 1.0 per 100,000 in  China9 and 1.57 for South  Asia11. On the 
other hand, the prevalence in Oceania and Japan are much  higher11.
Recent studies have reported a global incidence of ALS of between 0.6 and 3.8 per 100,000 person-year, with 
a pooled worldwide incidence of about 1.6–1.76,11,18.
In Europe the incidence is higher, ranging from 1.5 to 3.8 per 100.000 person-years in the decade of the 
 1990s19 and with a median incidence of 2.08 per 100,000 person-years1,6,11,17. Lower incidences are found in 
Southern Europe compared with Western and Northern  Europe18.
While incidence is usually much lower in Asia than it is in Europe, there is considerable variability among 
countries. The standardised incidence is about 0.83 per 100,000 person-years for East  Asia6,28, and 0.73 per 
100,000 person-years for South  Asia18. For the same period in Japan, however, the incidence of ALS was estimated 
at 2.2 per 100,000 person-years20 and 1.2 per 100,000 person-years in South  Korea6.
With respect to the Americas, the Global Burden of Disease estimated an age-standardized incidence for 
motor-neuron disease equal to 1.9 per 100,000 inhabitants for the USA in  200715, while Zapata et al. estimated 
an incidence of 1.4 per 100,000 person-years for Antioquia,  Colombia16.
Heterogeneity in both the incidence and prevalence of ALS is also present when other variables such 
as age and sex are considered. For example, incidence is between 1.3 and 1.5 times higher in men than in 
 women7,9,11,13,17,18,21–24 and it is also known that ALS is very rare prior to 40 years of age. The incidence of ALS 
reaches its maximum between 60 and 75  years9,22–24 or between 65 and 85  years11,17, depending on the study 
population.
To the best of our knowledge, no previous studies have analysed the prevalence or incidence of PLS and PMA. 
This may be because they are very rare diseases with a challenging differential diagnosis, thus making it difficult 
to carry out population-based studies.
The aim of this study was to estimate the prevalence and incidence of MND and its different diagnostic 
categories (ALS, PLS, and PMA), in the regions of Catalonia and Valencia (Spain) in the period 2011–2019.
Materials and methods
Design. Two Spanish Mediterranean regions were analysed, Catalonia and Valencia, which together com-
prise 26.72% of the total Spanish population and 53.67% of the Spanish population living in the Mediterranean 
basin (Catalonia 7,566,000 inhabitants and Valencia 4,975,000 inhabitants)25 (Fig. 1). These two neighbouring 
regions share climatic and sociodemographic conditions and have a common history (both belonged to the 
Kingdom of Aragon, one of the two kingdoms comprising Spain from the Middle Ages onwards), and much 
of the Catalan population originates from Valencia and vice-versa. Thus, it is likely that these populations have 
shared genetic and environmental risk factors of MND.
The study population was made up of the residents in the regions of Catalonia and Valencia between 1 Janu-
ary 2011 and 31 December 2019 (Catalonia) and between 1 January 2013 and 31 December 2018 (Valencia).
Two population-based cohorts were used, (one from Catalonia and the other from Valencia), encompassing 
the entire population of both regions. In both cohorts, clinical data were prospectively obtained, while some 
demographic data were retrospectively collected. The cohorts included all the patients who had been assessed at 
two Motor Neuron Disease Functional Units (MNDFU) in Spain: the Bellvitge University Hospital in Hospitalet 
de Llobregat in Catalonia, and the La Fe University and Polytechnic Hospital in Valencia, which act as referral 
units in the Catalan and Valencian regions, respectively. All the patients with MND seen in the Bellvitge Hospital 
since 2011 and the La Fe Hospital since 2013 were recorded prospectively in a database created for this purpose, 
and which included their demographic and clinical characteristics. All the patients studied were adults (specifi-
cally, the minimum age was 21 years in the Valencia cohort and 25 in the Catalonia cohort).
This study included the patients who had been evaluated in either of the two referral units during the time 
periods stated above and who met the following criteria: (1) a diagnosis of ALS, defined as the presence of UMN 
and LMN dysfunction in at least one body region at any time of the disease course, or LMN dysfunction in at 
least two body regions with a disease course typical of ALS (continuous non-invasive ventilation or death within 
four years from disease onset)26; (2) a diagnosis of definite PLS according to recent  criteria3; (3) PMA diagnosis, 
considered as the presence of isolated signs of LMN in at least two body regions with a slowly progressing dis-
ease course and a prolonged survival (> 4 years). Although there is no agreed consensus about the definition of 
PMA, to be consistent with the definition used for PLS, the recently proposed four-year criteria from Al-Chalabi 
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et al.1 was used. The diagnosis of MND and its different diagnostic categories (ALS, PLS and PMA) was made 
by specialists in MND.
All the census tracts of all the municipalities in Catalonia and Valencia were included; some with cases of 
MND and others (a much higher number) with no cases.
Variables. Response variable. Different models were estimated depending on the response variable. First, 
all MND cases were considered as the response variable, regardless of diagnostic category. Second, the follow-
ing diagnostic categories were considered as additional response variables: ALS, PLS and. PMA. This was done 
separately for each region (Catalonia and Valencia).
Individual control variables. Age at diagnosis and sex were included as individual explanatory variables. Age 
was further categorised into quintiles, taking the first quintile as the reference category. For the sex variable, male 
was considered as the reference category.
Patients were further categorized, according to the symptom of onset, into spinal, bulbar, respiratory and 
cognitive. The C9ORF72 expansion was studied in all MND patients, whereas SOD1 was sequenced in those 
familial MND patients not carrying the C9ORF72 expansion. In PMA patients, expansions in the androgen 
receptor gene were appropriately excluded.
Contextual control variables. The Spanish Epidemiology Association’s Deprivation Index 2011 (IP2011)27 cor-
responding to each of the census tracts of the municipalities of each of the two regions, was included as a con-
textual explanatory variable of interest. The IP2011 combines the information on six socioeconomic indicators, 
calculated for each census tract and based on the data collected in the Spanish Population and Housing Census 
 201128: percentage of the manual worker population, percentage of the temporary working population, percent-
age of the unemployed population, percentage of the population without complete compulsory schooling, and 
percentage of primary residences without access to the Internet The IP2011 was considered as the first compo-
nent of a sequential principal component analysis (PCA). First, a PCA with ten selected indicators was carried 
out (in addition to the six already mentioned, the following were included: the percentage of the population born 
in low-income countries and arrived in Spain after 2006, the percentage of the population born in low-income 
countries or born in Spain whose father or mother were born in low-income countries, the percentage of the 
population aged 65 or over, and the percentage of single-parent households with a woman in charge). Second, 
the ten indicators were correlated (using Spearman’s correlation coefficient) with the first component obtained 
through the PCA. Third, those indicators with correlations less than 0.5 were excluded. Finally, a PCA was car-
ried out using the six indicators finally considered (further information can be found  in27). The deprivation 
index was categorised into quintiles, taking the first quintile (i.e. the one corresponding to the less economically 
deprived census tracts) as the reference category.
The populations in each of the two regions, stratified by sex and age groups (women under 16 years, women 
aged 16 to 64 years, women ≥ 65 years, men under 16 years, men aged 16 to 64 years, men ≥ 65 years), were also 
included as contextual explanatory variables. The reference categories were the youngest categories for each sex. 
The total population at risk (population aged over 16 years) was used as the offset in the model for each of the 
two regions.
Population data by census tract, age, and sex was obtained from the Spanish Population and Housing Census 
 201128.
The graphic representation was produced based on the cartography of Catalonia (SRC ED50/UTM zone 31 N) 
and Valencia (SRC ED50/UTM zone 30 N) at the census tract level for  201129.
Figure 1.  Location of the Catalonia and Valencia regions.
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Statistical analysis. Selection bias is common in observational designs. That is, the analysed cohorts do 
not constitute a random sample of the population. Some subjects have a higher probability of being observed 
than others and, therefore, of being present in the sample. To this effect, the subjects that come into contact with 
one of the referral MNDFUs in the regions studied will be overrepresented.
If the selection was exogenous (also termed ignorable non-response, missing at random, or selection on 
observables), or in other words if the probability of a subject to be observed was identical for all subjects, 
weighting the sample to give less weight to the subjects actually observed would be sufficient. The weighting 
used would be the same as the inverse of the percentage of subjects among the population seen at each hospital, 
stratified by sex and age group. In epidemiology, this method of weighting is called standardisation by age and 
 sex30, considering the population covered by each hospital as the standard population.
However, these subjects are very likely to go to one of the referral MNDFUs, not only because they have 
symptoms of the onset of the disease, but also because there are unobserved factors that influence their use, 
which would be correlated with the non-observable factors that affect the response  variable31. In this sense, the 
population served by the MNDFU has a centre bias. In other words, they do not serve all the patients in the 
respective populations, but rather a part that may be biased (e.g. some centres send more patients than others; 
the patients they send are younger than the real population, etc.). In all cases, the probability of these subjects 
being observed is not the same for all the subjects. Therefore, weighting (standardisation) by age and sex would 
not correct the selection  bias31.
In this case (known as endogenous selection, also termed informative selection, missing not at random, or 
selection on unobservables), other more complex statistical methods should be used to obtain unbiased esti-
mates of prevalence and incidence, something that standardization by age and sex does not permit. Therefore, 
we chose a two-part  model32. In the first part, the probability of a subject being observed is estimated. These 
probabilities are then used as weightings in the second part of the model, where the prevalence and incidence 
are estimated, with the aim of correcting the non-randomness (in other words, the selection bias). The two parts 
are typically estimated using a two-part model called  Hurdle32,33. Thus, we specified a Hurdle model in which 
the two components were estimated  jointly33.
In the first part, the probability that an individual is being observed is modelled using a generalised linear 
mixed model (GLMM) with a binomial link. Included as variables associated with this probability are those that 
could explain that a subject was observed (in other words, that he/she had had contact with the UFMN of the 
corresponding hospital). More specifically, we considered individual and contextual variables.
Conditional on the true risk at the location xi , the probability of a case (of the corresponding response vari-
able) occurring in this location, P(xi) , i = 1, . . . , n , is distributed as a binomial.
n.trialsi is the population at risk of being a case in the location xi.
The link function is as follows:
where the subindex i indicates the census tract of the municipalities in each of the two regions and β are the 
coefficients of the explanatory variables ( eβ is the relative risk associated with each of them). η and S are random 
effects. η indicates the spatially unstructured individual heterogeneity. In other words, it indicates the non-
observable confounders associated with every individual which do not vary over time. S is a spatially structured 
random effect normally distributed with zero mean and a Mátérn covariance function:
where Kν is the modified Bessel function of the second type and order ν > 0 . ν is a smoother parameter, σ 2 is 
the variance and κ > 0 is related to the range ( ρ =
√
8ν/κ ), the distance to which the spatial correlation is close 
to 0.1.
Because of the large number of census tracts with no cases, in the second part a GLMM with Zero Inflated 
Poisson distribution is used to model the number of patients diagnosed for each of the response variables and 
by census tract. The same explanatory variables as in the first part of the model are included.
Conditional to the true risk in the location xi , the mathematic expectation of cases of the response variable 
occurring in each of the census tracts, θ(xi) , i = 1, . . . , n , is distributed as a Poisson:
In this case, the link function is as follows:
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The definition of the parameters, the variables, and the random effects, is the same as described previously.
In both parts, random effects that include non-observed confounders are also included, capturing individual 
heterogeneity (specific for each of the two parts) and spatial dependence. That is to say, areas that are close in 
space show more similar prevalence and incidence than areas that are not close (common to the two parts). In 
the model used to estimate the incidence, an additional random effect was included to control for the existence 
of temporal trends (also common to the two parts). The temporal dependence was controlled using a random 
effect structured as a random walk of order  134 (further details can be found  elsewhere33).
Both parts were estimated simultaneously following a Bayesian perspective, using the Integrated Nested 
Laplace Approximation (INLA)  approach35. Priors that penalize the complexity (PC priors)36 and have been 
found to be very robust were used.
Consequently, point and interval estimates were obtained for the prevalence and the incidence, both at the 
level of the region to which the hospital belongs, and at the level of census tract of each of their municipalities.
Last, the prevalence and incidence of MND per 100,000 inhabitants is represented on the map of the census 
tracts of Catalonia and Valencia using the mapping by census tracts of the Population and Housing Census  201128, 
and the “leaflet”  library37 (Figs. 3 and 4).
All analyses were carried out using the free software R (version 3.6.2)38, through the INLA  package35,39.
Ethics approval. The data for this study came from an anonymised clinical administrative database and 
only the lead researcher, where necessary, had access to the identity of each individual. The information in 
this administrative clinical database was obtained through the informed consent of the patients. In any case, 
all methods of this study were carried out in accordance with relevant guidelines and regulations, having been 
revised and approved by the Committee of Ethics and Clinical Research (CEIC) of the Bellvitge University 
Hospital.
Results
Between 2013 and 2018, 259 MND patients were recorded in the Valencian MNDFU, whereas 591 cases were 
recorded in the Catalonian MNDFU between 2013 and 2019. Their demographic and clinical characteristics can 
be found in Tables 1, 2 and 3. In most of the census tracts (93.0% of the census tracts for Valencia, and 89.4% for 
Catalonia) no cases of MND were found (Table 4). 6.6% and 9.6% of the census tracts of Valencia and Catalonia, 














Table 1.  Descriptive analysis of demographic and clinical characteristics by region for each of the diagnostic 
categories. Amyotrophic Lateral Sclerosis (ALS). a First row: mean (sd). Second row: median (1st–3rd 
quartiles). Third row: (min–max).
Demographic and clinical characteristics stratified by region
Valencia (n = 219) Catalonia (n = 524)
Variables
Sex [n (%)]
Women 99 (45.2) 246 (46.9)
Men 120 (54.8) 278 (53.1)
Age at  diagnosisa
62.79 (11.30) 63.68 (12.47)
63 (56.0–70.0) 65.0 (56.0–73.0)
(21–86) (25–89)
Age at diagnosis in quintiles [n (%)]
 <  = 53/ <  = 52 35 (16.0) 92 (17.6)
(53–59]/(52–61] 50 (22.8) 105 (20.0)
(59–66]/(61,67] 41 (18.7) 109 (20.8)
(66–71]/(67,74.6] 48 (21.9) 105 (20.0)
 > 71/ > 74.6 45 (20.5) 113 (21.6)
Symptom at onset [n (%)]
Bulbar 62 (28.31) 155 (29.6) (n = 512)
Spinal 146 (66.67) 324 (61.8) (n = 512)
Respiratory 4 (1.83) 20 (3.8) (n = 512)
Cognitive (dementia) 7 (3.20) 13 (2.5) (n = 512)
C9orf72 [n (%)] 17 (8.25) (n = 206) 33 (8.82) (n = 374)
SOD1 [n (%)] 5 (2.43) (n = 206) 2 (1.87) (n = 107)
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Table 2.  Descriptive analysis of demographic and clinical characteristics by region for each of the diagnostic 
categories. Progressive Muscular Atrophy (PMA) a First row: mean (sd). Second row: median (1st-3rd 
quartiles). Third row: (min–max).
Demographic and clinical characteristics stratified by region
Valencia (n = 27) Catalonia (n = 14)
Variables
Sex [n (%)]
Women 5 (18.5) 2 (14.3)
Men 22 (81.5) 12 (85.7)
Age at  diagnosisa
60.70 (14.28) 55.50 (13.33)
64 (52.0–72.0) 54.0 (42.8–68.0)
(23–78) (36–76)
Age at diagnosis in quintiles [n (%)]
 <  = 53/ <  = 52 7 (25.9) 7 (50.0)
(53–59]/(52–61] 3 (11.1) 1 (7.1)
(59–66]/(61,67] 5 (18.5) 2 (14.3)
(66–71]/(67,74.6] 5 (18.5) 3 (21.4)
 > 71/ > 74.6 7 (25.9) 1 (7.1)
Symptom at onset [n (%)]
Bulbar 2 (7.4) 0 (0.0) (n = 6)
Spinal 25 (92.6) 6 (100.0) (n = 6)
Respiratory 0 (0.0) 0 (0.0) (n = 6)
Cognitive (dementia) 0 (0.0) 0 (0.0) (n = 6)
C9orf72 [n (%)] 0 (0.0) (n = 26) 0 (0.0) (n = 13)
SOD1 [n (%)] 3 (11.54) (n = 26) 0 (0.0) (n = 4)
Table 3.  Descriptive analysis of demographic and clinical characteristics by region for each of the diagnostic 
categories. Primary Lateral Sclerosis (PLS). a First row: mean (sd). Second row: median (1st–3rd quartiles). 
Third row: (min–max).
Demographic and clinical characteristics stratified by region
Valencia (n = 10) Catalonia (n = 4)
Variables
Sex [n (%)]
Women 5 (50.0) 3 (75.0)
Men 5 (50.0) 1 (25.0)
Age at  diagnosisa
59.20 (12.48) 56.00 (12.52)
60 (55.75–68.25) 60.5 (42.75–64.75)
(28–73) (38–65)
Age at diagnosis in quintiles [n (%)]
 <  = 53/ <  = 52 1 (10.0) 1 (25.0)
(53–59]/(52–61] 3 (30.0) 1 (25.0)
(59–66]/(61,67] 3 (30.0) 2 (50.0)
(66–71]/(67,74.6] 2 (20.0) 0 (0.0)
 > 71/ > 74.6 1 (10.0) 0 (0.0)
Symptom at onset [n (%)]
Bulbar 3 (30.0) NA
Spinal 7 (70.0) NA
Respiratory 0 (0.0) NA
Cognitive (dementia) 0 (0.0) NA
C9orf72 [n (%)] 0 (0.0) 0 (0.0) (n = 3)
SOD1 [n (%)] 0 (0.0) 0 (0.0) (n = 0)No test available
7
Vol.:(0123456789)
Scientific Reports |         (2021) 11:6207  | https://doi.org/10.1038/s41598-021-85395-z
www.nature.com/scientificreports/
respectively, had just one case of MND. The maximum number of cases of MND in a census tract was three. 
However, although the populational structure is very similar in Catalonia and Valencia (the percentage of the 
population aged 65 years and over was 16.70% in Catalonia and 16.90% in Valencia), the census tracts from the 
municipalities of Valencia were much more deprived than those in Catalonia (average of 0.082 in Valencia and 
− 0.470 in Catalonia, median of 0.110 in Valencia and − 0.503 in Catalonia).
Table 5 shows the main demographic and clinical characteristics of patients diagnosed with MND, strati-
fied by region. Mean age at diagnosis was 62.43 (median = 63) years in Valencia and 63.51 (median = 65) years 
in Catalonia. In both regions, there were more men than women (57.9% in Valencia and 55.5% in Catalonia). 
When the diagnostic category is taken into account, 85.5% of all MND cases in Valencia were ALS, 10.5% were 
PMA, and 3.9% PLS. The same pattern was observed for Catalonia, with ALS being the most frequent diagnosis 
(96.7%), followed by PMA (2.6%) and PLS (0.7%). Among ALS patients in Valencia, 66.67% had spinal ALS, 
28.31% bulbar ALS, 3.20% cognitive onset, and 1.83% respiratory ALS. Similar patterns were seen in Catalonia: 
64.12% spinal ALS, 29.58% bulbar ALS, 3.82% respiratory ALS, and 2.48% cognitive onset. Finally, in Valencia 
6.95% of the patients carried a C9ORF72 expansion and 3.27% the SOD1 mutation, while in Catalonia it was 
7.67% and 2.22%, respectively.
Table 6 shows the estimated prevalence and incidence of MND (point estimation and credibility interval at 
95%), for the two regions, as well as by diagnostic category, per 100,000 inhabitants. Although the point estimator 
Table 4.  Description of the contextual variables by census tract. MND moto neuron disease, ALS amyotrophic 
lateral sclerosis, PMA progressive muscular atrophy, PLS primary lateral sclerosis.
Description of the contextual variables by por census tract
Valencia (n = 259) Catalonia (n = 591)
Variables
Census tracts 3,473 5,018
Cases MND by tract [n (%)]
0 3,229 (93.0) 4,485 (89.4)
1 230 (6.6) 481 (9.6)
2 13 (0.4) 46 (0.9)
3 1 (0.0) 6 (0.1)
Cases ALS by tract [n (%)]
0 3,264 (94.0) 4,538 (90.4)
1 199 (5.7) 440 (8.8)
2 10 (0.3) 37 (0.7)
3 0 (0.0) 3 (0.1)
Cases PMA by tract [n (%)]
0 3,447 (99.3) 5,004 (99.7)
1 25 (8.4) 14 (0.3)
2 1 (0.0) 0 (0.0)
Cases PLS by tract [n (%)]
0 3,463 (99.7) 5,014 (99.9)
1 10 (0.3) 4 (0.1)
Total population [n] 4,990,470 7,472,920
Population under 16 years 808,805 1,246,595 (missing = 64)
Population over 16 years 4,180,520 6,226,325
Population 16 to 64 years 3,336,200 4,978,106
Population 65 years and over 843,265 (missing = 14) 1,248,219
Men [n] 2,481,257 3,701,280
Men under 16 years 416,825 (missing = 17) 645,025 (missing = 114)
Men over 16 years 2,060,847 (missing = 17) 3,056,415
Men 16 to 64 1,693,039 2,520,051 (missing = 12)
Men 65 years and over 370,258 (missing = 33) 531,909 (missing = 72)
Women [n] 2,508,893 3,771,595
Women under 16 years 391,980 (missing = 17) 601,570 (missing = 122)
Women over 16 years 2,114,278 (missing = 15) 3,170,035
Women 16 to 64 1,643,225 2,456,554 (missing = 15)
Women 65 years and over 473,083 (missing = 31) 707,914 (missing = 74)
Deprivation index Mean (standard deviation) 0.082 (0.862) − 0.470 (0.784)
Median (Q1–Q3) 0.110 (− 0.423–0.601) − 0.503 (− 1.015–0.005)
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Table 5.  Descriptive analysis of demographic and clinical characteristics by region. All patients. ALS 
Amyotrophic Lateral Sclerosis, PMA Progressive Muscular Atrophy, PLS Primary Lateral Sclerosis. a First row: 
mean (sd). Second row: median (1st-3rd quartiles). Third row: (min–max).
Demographic and clinical characteristics stratified by region
Valencia (n = 259) Catalonia (n = 591)
Variables
Sex [n (%)]
Women 109 (42.1) 263 (44.5)
Men 150 (57.9) 328 (55.5)
Age et al.  diagnosisa
62.43 (11.67) 63.51 (12.54)
63 (56.0–70.0) 65.0 (56.0–73.0)
(21–86) (25–89)
Age at diagnosis in quintiles [n (%)]
 <  = 53/ <  = 52 45 (17.4) 106 (17.9)
(53–59]/(52–61] 57 (22.0) 117 (19.8)
(59–66]/(61,67] 49 (18.9) 122 (20.6)
(66–71]/(67,74.6] 55 (21.2) 121 (20.5)
 > 71/ > 74.6 53 (20.5) 125 (21.2)
Definite diagnosis [n (%)]
ALS 219 (85.5) 524 (96.7)
PMA 27 (10.5) 14 (2.6)
PLS 10 (3.9) 4 (0.7)
Symptom at onset [n (%)]
Bulbar 62 (28.31) 155 (29.58)
Spinal 146 (66.67) 336 (64.12)
Respiratory 4 (1.83) 20 (3.82)
Cognitive (dementia) 7 (3.20) 13 (2.48)
C9orf72 [n (%)] 17 (6.94) (n = 245) 33 (7.67) (n = 430)
SOD1 [n (%)] 8 (3.27) (n = 245) 3 (2.22) (n = 135)
Table 6.  Estimation of the prevalence and incidence of motor neuron disease (MND) and its variants 
in the regions of Valencia and Catalonia (2013–2018 and 2011–2019). MND Moto Neuron Disease, ALS 
Amyotrophic Lateral Sclerosis, PMA Progressive Muscular Atrophy, PLS Primary Lateral Sclerosis. a Point 
estimate (credibility interval at 95%).
Estimation of the prevalence and incidence of mnd and variants, stratified by region
Valencia (n = 259) Catalonia (n = 591)
Prevalence (per 100,000 inhabitants)
Variables
MNDa 4.216 (2.652–6.334) 5.627 (3.990–7.662)
Definite diagnosisa
ALS 3.249 (1.911–5.120) 4.721 (3.248–6.608)
PMA 0.480 (0.065–1.650) 0.602 (0.008–0.634)
PLS 0.378 (0.046–1.896) 0.662 (0.000–1.987)
Incidence (per 100,000 person-years)
Variables
MNDa 1.390 (0.822–2.165) 2.346 (1.682–3.152)
Definite diagnosisa
ALS 1.080 (0.598–1.754) 1.935 (1.351–2.656)
PMA 0.222 (0.009–1.027) 0.415 (0.225–0.628)
PLS 0.202 (1.306e-09–0.564) 0.476 (0.409–0.544)
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of MND prevalence was higher for Catalonia than for Valencia (5.627 vs 4.216, respectively), there were no sta-
tistically significant differences between the two regions, given that the credibility intervals overlapped (shown 
graphically in the forest plot in Fig. 2a). Likewise, although the prevalence of ALS, PMA and PLS observed in 
Catalonia were always above those of Valencia (ALS 4.72 vs 3.25, PMA 0.61 vs 0.48, PLS 0.66 vs 0.38, respec-
tively), the differences between the two regions were not statistically significant.
Regarding the estimation of the incidence of MND and their variants by region, Table 6 and Fig. 2b show a 
greater incidence in Catalonia than in Valencia: MND (2.346 vs 1.390 per 100,000 person-year, respectively), 
ALS (4.721 vs 3.249 per 100,000 person-year, respectively), PMA (0.415 vs 0.222 per 100,000 person-year, respec-
tively) and PLS (0.476 vs 0.202 per 100,000 person-year, respectively). However, differences were not statistically 
significant, given that the credibility intervals overlapped in the two cases.
Finally, Fig. 3a,b show the estimated prevalence by census tract in Catalonia and Valencia, and Fig. 4a,b are 
a graphic representation of the estimated incidence by census tract. The census tracts whose at risk populations 
are very small must be interpreted with caution.
In summary, and using the intersection regions of the credibility intervals of the two regions, it was estimated 
with a 95% probability for the period 2011–2019 (Catalonia 2011–2019, Valencia 2013–2018) that the prevalence 
of MND would be between 3.990 and 6.334 per 100,000 inhabitants; the prevalence of ALS between 3.248 and 
5.120 per 100,000 inhabitants; the prevalence of PMA between 0.065 and 0.634 per 100,000 inhabitants; and the 
prevalence of PLS between 0.046 and 1.896 per 100,000 inhabitants.
Figure 2.  (a) Forest plot of the estimated prevalence per 100,000 inhabitants in Catalonia and Valencia. (b) 
Forest plot of the estimated incidence per 100,000 person-years in Catalonia and Valencia.
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Regarding incidence, again with a 95% probability and for the period 2011–2019 (Catalonia 2011–2019, 
Valencia 2013–2018), it was estimated as being between 1.682 and 2.165 per 100,000 person/years for MND; 
between 1.351 and 1.754 per 100,000 person/years for ALS; between 0.225 and 0.628 per 100,000 person/years 
for PMA; and between 0.409 and 0.544 per 100,000 person/years for PLS.
Discussion
This work makes a number of important contributions. First, it provides prevalence and incidence estimators 
not only of MND itself, but also of ALS, PLS and PMA. Second, an original prevalence and incidence estimation 
method is proposed, that controls the selection bias caused by not using random samples from the population. 
Third, to meet the objective of this study, both individual and contextual databases from various and different 
sources are needed, which is where Real-World Data takes on importance. This approach is used in this work to 
combine the individual-level databases with a contextual-level database containing population data and data on 
the socioeconomic level of the area where the subjects live. Fourth, the existence of non-observed confounders 
and the spatial and temporal dependence inherent to the data used are also controlled for and last but not least, 
the study compares the prevalence and incidence in two different Spanish regions, allowing for any differential 
risk or protective factors in them to be assessed.
Figure 3.  (a) Map of the estimated prevalence per census tract across the study region (Catalonia). Own 
construction using the leaflet  package37, version 2.0.3 [https ://CRAN.R-proje ct.org/packa ge=leafl et]. (b) Map of 
the estimated prevalence per census tract across the study region (Valencia). Own construction using the leaflet 
 package37, version 2.0.3 [https ://CRAN.R-proje ct.org/packa ge=leafl et]. 
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Characteristics of the patients. Although the cohorts studied were not random samples from the popu-
lation, the demographic and clinical characteristics of the ALS patients (Table 1) are almost identical to those of 
previous population-based studies in the Mediterranean  area40, suggesting that our cohorts were representative 
of the ALS populations in Valencia and Catalonia, respectively. Moreover, the frequency of the C9ORF72 expan-
sion in both ALS cohorts (8.2–8.8%) was very similar to that previously found in a Spanish study (7.2%)41. The 
frequency of the SOD1 mutation (1.9–2.4%) was somewhat lower than that previously reported (4.25%)42, prob-
ably because, unlike C9ORF72, SOD1 is not routinely studied in sporadic ALS patients.
As  expected2, PLS represented approximately 3% of MND patients and their characteristics were similar to 
previously described cohorts of PLS patients. Specifically, they were younger than the ALS patients (Tables 2 
and 3). PMA data must be compared with previous reports with caution, since there has previously been no 
uniform definition of PMA. For this study, the recently proposed definition of ‘restricted LMN signs for at least 
four years’1 was used to clearly differentiate these patients from LMN-predominant ALS patients. Despite pos-
sible differences in the definition, the characteristics of the PMA patients were similar to previous  reports43,44: 
a frequency of 2.6–10.5% of MND patients, a striking male and spinal-onset predominance, and a similar age 
to that of ALS patients. Importantly, in the PMA patients’ expansions in the androgen receptor gene had been 
appropriately excluded, but three SOD1 mutations were found. This is not surprising, since a genetic overlap 
between ALS and PMA has been previously  found45.
Figure 4.  (a) Map of the estimated incidence per census tract across the study region (Catalonia). Own 
construction using the leaflet  package37, version 2.0.3 [https ://CRAN.R-proje ct.org/packa ge=leafl et]. (b) Map of 
the estimated incidence per census tract across the study region (Valencia). Own construction using the leaflet 
 package37, version 2.0.3 [https ://CRAN.R-proje ct.org/packa ge=leafl et]. 
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Prevalence and incidence. To the best of our knowledge, this is the first study in which incidence and 
prevalence of MND, including ALS, PMA and PLS, have been assessed.
In line with the literature, ALS was the most frequent MND, comprising 85.5–96.7% of the MND patients. 
The prevalence and incidence estimates of both MND and ALS is within the ranges described in the literature (a 
prevalence of between 4.1 and 8.4 per 100.000 person-year and an incidence of between 0.6 and 3.8 per 100.000 
person-year6).
More specifically, the prevalence estimates in this study were very similar to those reported by Chiò et al.9 
(median prevalence of 4.48; interquartile range, IQR, 3.03–6.70) and fairly similar to those found by Orsini et al.10 
(a prevalence of between 4 and 6 per 100,000 inhabitants); Tesauro et al.8 (5 per 100,000 inhabitants); Pradas 
et al.46 (prevalence for Catalonia of 5.4 per 100,000 inhabitants); and Belbasis et al.7 (5.4 per 100,000 inhabitants).
The incidence estimates found in this study were almost identical to those reported by Marin et al.18 (stand-
ardised incidence of 1.68, 95% CI 1.50–1.85 all per 100.000 person-year) and in the range found by Chiò et al.9 
(median incidence in Europe of 2.08 per 100,000 person-year, IQR: 1.47–2.43); Zarei et al.18 (incidence in Europe 
of between 1.5 and 2.7 per 100,000 person-year) and Santurtun et al.47 (incidence in Spain of between 1 and 3 
cases per 100,000 person-year).
However, the incidence estimates found here differ from those described by Pradas et al.46, who estimated 
an incidence for Catalonia below the credibility interval found in this study (standardised incidence of 1.4 per 
100,000 person-year vs. 1.682 per 100,000 person-year, respectively).
Notably, these comparisons must be made with caution. The estimators for prevalence and incidence present 
a huge heterogeneity. This could be due to the heterogeneity of the disease itself, to the structure of age and sex of 
the population studied, to geographical variables, to environmental factors, to the period under study (2011–2019 
in this case, 1995–2011 in Chiò et al.9, the decade of the 1990s in Zarei et al.19 and 2013 in Santurtun et al.47 and 
Pradas et al.46), to the different diagnostic criteria, to different clinical practices, to the genetic predisposition 
of the subjects, to the type and sources of data used, to the type of design (prospective-retrospective, cohort-
transversal study), and/or to the method used to calculate the prevalence and incidence (crude, standardised and 
multivariate models). An additional significant problem is that many of the authors do not explain the method 
they used to estimate the incidence and the prevalence.
Regarding PMA and PLS, there have been no previous epidemiological studies on these diagnostic categories, 
although their incidence has been estimated at < 0.1 per 100,0002,43. The estimated incidence found in this study 
ranges from 0.2 to 0.6 in both categories, suggesting a higher incidence than previously thought. However, these 
point estimates must be considered with caution given the wide confidence intervals.
In the present study, the point estimates of both prevalence and incidence for Valencia were, in all cases, lower 
than those for Catalonia. Given that the structure of age and sex was similar for both regions, and that economic 
deprivation was controlled for (possible risk factor), we believe that such differences are not due to the pres-
ence of additional risk factors because these are two Mediterranean regions with similar characteristics. These 
differences could be attributed to the different coverage provided by the referral hospitals in the two regions. 
While health care is public and universal in both regions, they each have their own organisation in terms of 
care, which could alter patient referral criteria and percentages. Furthermore, the population in Valencia is more 
dispersed geographically (39.6% of its inhabitants live in the metropolitan area of Valencia vs 71.5% living in 
the metropolitan area of Barcelona in Catalonia), thus (possibly) limiting access to the La Fe Hospital’s UFMN. 
Despite this, differences in prevalence and incidence between areas were not statistically significant, since there 
was a considerable overlap in the confidence intervals. This suggests that the methodological approach is robust 
enough to account for local differences.
This study has some limitations. First, despite clinical data being prospectively obtained, some demographic 
data were collected retrospectively. This retrospective feature may have implied that the point estimators that we 
have obtained have been lower than those obtained in prospective cohorts of other European studies. Second, 
some patients that did not meet the criteria for ALS, PLS or PMA (according to the definition used here) when 
the study was carried out. These patients, while having an MND, were not included in the present study since 
they did not yet have a confirmed diagnosis which would have enabled them to be classified into one of the 
categories. Therefore, both incidence and prevalence may be greater than those estimated. However, this limita-
tion applies for all previous epidemiological studies regardless of the definition used. Moreover, for this study 
we used the most recent consensus definitions. Third, the studied period is different in the two hospitals and the 
coverage of cases may also be different. Nonetheless, the method is sufficiently robust to give similar results, at 
least regarding the interval estimate. Last, when the population at risk is very small, the point estimators can be 
relatively unstable. Therefore, it is better to produce aggregated results and to interpret Figs. 3 and 4 with cau-
tion. Furthermore, point estimates must never be interpreted in isolation but rather together with their interval 
estimators (as was done throughout this study) which, with a certain probability, contain the true value of the 
parameter (i.e. prevalence and incidence).
This paper has several strengths. First, this is the first study to estimate the prevalence and incidence of PLS 
and PMA. Second, contrary to the studies based on information systems, here the diagnosis of MND and its 
variants was supervised by specialists in MND in leading hospitals, thus minimizing the possibility of diagnostic 
errors. Third, in Spain there are only two studies estimating the prevalence and incidence of ALS using infor-
mation from prior to 2011, neither of which provide estimates of MND according to the different diagnostic 
categories cited previously or are differentiated by region. Fourth, we propose an unbiased estimate of prevalence 
and incidence when, as in our case, there is selection bias due to the lack of random samples and, in addition, 
this selection bias is endogenous. Moreover, the sample used in this study comprised a large number of patients 
from two Spanish referral hospitals. Last, despite the different coverage in the two hospitals analysed, the fact 
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that both the prevalence and the incidence estimators (by interval) overlapped can be taken as in indication that 
the method proposed enables the selection bias to be controlled for.
Conclusion
In summary, within the context of RWD, we have used an original estimation method which has allowed us to 
control for the selection bias resulting from not using random samples of the population. With this method, 
confounders, both observed and unobserved, individually and contextually, were appropriately controlled. Using 
this method, estimators were obtained of both the prevalence and the incidence of MND and its different cat-
egories: prevalence of MND, with a 95% probability, between 3.990 and 6.334 per 100,000 inhabitants; between 
3.248 and 5.120 per 100,000 inhabitants for ALS; between 0.065 and 0.634 per 100,000 inhabitants for PMA; 
and between 0.046 and 1.896 per 100,000 inhabitants for PLS; incidence of MND, between 1.682 and 2.165 per 
100,000 person/years; between 1.351 and 1.754 per 100,000 person-years for ALS; between 0.225 and 0.628 per 
100,000 person-years for PMA; and between 0.409 and 0.544 per 100,000 person-year for PLS.
Using an original estimation method based on RWD, the prevalence and incidence of ALS and, for the first 
time, of PMA and PLS, in two Spanish Mediterranean regions was obtained. The data produced are similar to 
those of other regions and do not differ greatly from data reported previously for ALS, suggesting that the pro-
posed method is robust and that neither region presents differential risk or protective factors.
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